Less futuristic are what Drues referred to as "multiple combination products."
These might incorporate two biologics, as well as a drug or two attached to a biologic-based medical device that would eventually break down in a patient's system once the attached drugs and biologics are completely released. As he suggests on screen 1 of this issue, today's drug-eluting stents are primitive compared with what we'll have in the future.
Those in the packaging community would be wise to be ready to meet these challenging opportunities—but how? After Drues's presentation, I realized brighter minds than my own will need to determine how to package these sensitive combination products. A good start would be the Food and Drug Administration's Office of Combination Products. [HCP]
These might incorporate two biologics, as well as a drug or two attached to a biologic-based medical device that would eventually break down in a patient's system once the attached drugs and biologics are completely released. As he suggests on screen 1 of this issue, today's drug-eluting stents are primitive compared with what we'll have in the future.
Those in the packaging community would be wise to be ready to meet these challenging opportunities—but how? After Drues's presentation, I realized brighter minds than my own will need to determine how to package these sensitive combination products. A good start would be the Food and Drug Administration's Office of Combination Products. [HCP]
